GlobeNewswire: Immune Therapeutics, Inc. Contains the last 10 of 39 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T15:14:55ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/12/16/1961105/0/en/Immune-Therapeutics-Announces-Plan-to-Acquire-Aletheia-Therapeutics-to-Create-a-New-Precision-Oncology-Company.html?f=22&fvtc=4&fvtv=28655Immune Therapeutics Announces Plan to Acquire Aletheia Therapeutics to Create a New Precision Oncology Company2019-12-16T16:11:16Z<![CDATA[The Planned Acquisition Would Enhance the Management Team, Provide Capital and Bring Additional Oncology Assets to Immune’s Pipeline The Planned Acquisition Would Enhance the Management Team, Provide Capital and Bring Additional Oncology Assets to Immune’s Pipeline]]>https://www.globenewswire.com/news-release/2019/10/28/1936386/0/en/Immune-Therapeutics-Today-Announces-Approval-of-a-Reverse-Stock-Split-and-Name-Change.html?f=22&fvtc=4&fvtv=28655Immune Therapeutics Today Announces Approval of a Reverse Stock Split and Name Change2019-10-28T13:30:00Z<![CDATA[ORLANDO, Fla., Oct. 28, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC:IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage oncology biopharmaceutical company focused on the development therapies for the treatment of cancer using an immune therapy and a systems biology approach today announced that its Board of Directors and a majority of its shareholders have approved a reverse stock split of the Company’s issued and outstanding common shares at a ratio of 1,000 to 1 and a change of the Company’s name to Forte Biotechnology, Inc. The reverse share split will uniformly affect all issued and outstanding Immune common shares. No fractional shares will be issued in connection with the reverse share split and the Company will round down any fractional shares resulting from the reverse split. The par value of Immune Therapeutics’ common shares will remain unchanged at $0.0001 per share following the reverse share split. The reverse share split will not reduce Immune Therapeutics’ authorized number of common shares.]]>https://www.globenewswire.com/news-release/2019/10/22/1933469/0/en/Immune-Therapeutics-Inc-Announces-Advisory-Board-Appointments.html?f=22&fvtc=4&fvtv=28655Immune Therapeutics, Inc. Announces Advisory Board Appointments2019-10-22T15:03:30Z<![CDATA[ORLANDO, Fla., Oct. 22, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune" “IMUN” or the "Company"), a clinical late-stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS announced today that Dr. Robert Buckheit, Jr. will join the Scientific Advisory Board (“SAB”) of Immune Therapeutics.]]>https://www.globenewswire.com/news-release/2019/09/26/1921292/0/en/Immune-Therapeutics-Inc-Management-Advises-All-Shareholders-to-Vote-Their-Proxy-Card-Today.html?f=22&fvtc=4&fvtv=28655Immune Therapeutics Inc. Management Advises All Shareholders to Vote Their Proxy Card Today2019-09-26T13:00:00Z<![CDATA[Immune Therapeutics Inc. Management Urges Shareholders to Vote Yes and Support the Company's Three Proposals Immune Therapeutics Inc. Management Urges Shareholders to Vote Yes and Support the Company's Three Proposals]]>https://www.globenewswire.com/news-release/2019/09/23/1919242/0/en/Immune-Therapeutics-Today-Announces-Appointment-of-Michael-K-Handley-as-its-new-Chief-Executive-Officer-and-Member-of-the-Board-of-Directors.html?f=22&fvtc=4&fvtv=28655Immune Therapeutics Today Announces Appointment of Michael K. Handley as its new Chief Executive Officer and Member of the Board of Directors2019-09-23T13:30:00Z<![CDATA[ORLANDO, Fla., Sept. 23, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC:IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage T-Cell Activation biopharmaceutical company focused on the development immunotherapies for the treatment of autoimmune and inflammatory conditions, cancer, HIV/AIDS and animal diseases on a global basis is pleased to announce the appointment of Michael K. Handley as the new Chief Executive Officer of Immune Therapeutics’ and Member of the Board of Directors. IMUN also announces the resignation of its former CEO, and Director, Noreen Griffin.]]>https://www.globenewswire.com/news-release/2019/09/10/1913553/0/en/Immune-Therapeutics-Revises-and-Resends-Proxy-Statement.html?f=22&fvtc=4&fvtv=28655Immune Therapeutics Revises and Resends Proxy Statement2019-09-10T13:30:00Z<![CDATA[ORLANDO, Fla., Sept. 10, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC: IMUN) ("Immune," “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS, has filed a Revised Definitive Proxy Statement (the “Revised Proxy Statement”) due to the discovery that, as a result of an error outside of the Company’s control, shareholders of IMUN holding their shares through a broker in “street name” did not receive copies of the Company’s proxy materials mailed on or around April 30, 2019.]]>https://www.globenewswire.com/news-release/2019/05/15/1825335/0/en/Immune-Therapeutics-Inc-Provides-Shareholder-Update-on-14A.html?f=22&fvtc=4&fvtv=28655Immune Therapeutics, Inc. Provides Shareholder Update on 14A2019-05-15T13:36:42Z<![CDATA[ORLANDO, Fla., May 15, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS announced today provides update on status of 14A.]]>https://www.globenewswire.com/news-release/2019/01/09/1683002/0/en/Immune-Therapeutics-welcomes-Kevin-Phelps-to-Board-of-Directors.html?f=22&fvtc=4&fvtv=28655Immune Therapeutics welcomes Kevin Phelps to Board of Directors2019-01-09T18:44:38Z<![CDATA[ORLANDO, Fla., Jan. 09, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTCQB:IMUN) (“Immune Therapeutics”, “IMUN” or the “Company”), a late stage clinical biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS has announced today that Kevin Phelps, CPA, has been appointed to its Board of Directors.]]>https://www.globenewswire.com/news-release/2018/12/13/1666792/0/en/Research-on-Lodonal-LDN-for-HIV-related-GI-complications-and-Inflammation-featured-in-A-U-Magazine.html?f=22&fvtc=4&fvtv=28655Research on Lodonal (“LDN”) for HIV-related GI complications, and Inflammation featured in A&U Magazine2018-12-13T15:24:33Z<![CDATA[ORLANDO, Fla., Dec. 13, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS announced today that their lead therapy, Lodonal™ (LDN), was featured in an article published in A&U Magazine (https://issuu.com/aumagazine/docs/a_u_december2018 pg. 59).]]>https://www.globenewswire.com/news-release/2018/09/06/1566509/0/en/Immune-Therapeutics-Welcomes-Amb-Jack-Brewer-to-the-Board-of-Directors.html?f=22&fvtc=4&fvtv=28655Immune Therapeutics Welcomes Amb. Jack Brewer to the Board of Directors2018-09-06T13:30:00Z<![CDATA[ORLANDO, Fla., Sept. 06, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC:IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage T-Cell Activation biopharmaceutical company focused on the development immunotherapies for the treatment of autoimmune and inflammatory conditions, cancer, HIV/AIDS and animal diseases on a global basis, announced today that Mr. Jack Brewer, MBA, has joined the Company as a member of the Board of Directors.]]>